Skip to content
ClinCalc Pro
Menu
Local anaesthetic with vasoconstrictor Pregnancy: Animal studies with articaine 40 mg/ml + adrenaline 10 micrograms/ml, as well as with articaine alone, have not shown adverse effects on pregnancy, embryonal/foetal development, birth or postnatal development (see section 5.3). Animal studies have shown that adrenaline is toxic to reproduction at doses higher than maximal recommended dose (see section 5.3). There is no experience of the use of articaine in pregnant women, except during childbirth. Adrenaline and articaine cross the placental barrier, although articaine does so to a lesser extent than other local anaesthetics. Serum concentrations of articaine measured in newborn infants were approx. 30% of maternal levels. In the event of inadvertent intravascular administration in the mother, adrenaline can reduce uterine perfusion. During pregnancy, Septanest/Artikent/Bartinest/Isonest 1:100,000 should only be used after a careful analysis of the benefit-to-risk ratio has been made. On account of its lower adrenaline content, the use of Septanest/Artikent/Bartinest/Isonest 1:200,000 over Septanest/Artikent/Bartinest/Isonest 1:100,000 should be preferred. Breastfeeding: As a result of the rapid drop in serum levels and rapid elimination, clinically relevant quantities of articaine are not found in breast milk. Adrenaline passes into breast milk but also has a short half-life. It is not usually necessary to suspend breast-feeding for short-term use, starting from 5 hours following anesthesia. Fertility: Animal studies with articaine 40 mg/ml + adrenaline 10 micrograms/ml have not shown effects on fertility (see section 5.3). At therapeutic doses, adverse effects on human fertility are not expected.

Adrenaline with articaine hydrochloride

Brand names: Septanest

Used in: Epistaxis (Nosebleed)

A dental local anaesthetic injection combining articaine, an amide local anaesthetic, with adrenaline as a vasoconstrictor, used for infiltration and nerve-block anaesthesia in dentistry.

Adult dose

Dose: Septanest / Artikent / Bartinest / Isonest 1:200,000 (articaine hydrochloride with adrenaline 1:200,000; per 1.7 ml cartridge: articaine hydrochloride 68.000 mg and adrenaline 8.50 micrograms; per 2.2 ml cartridge: articaine hydrochloride 88.000 mg and adrenaline 11.00 micrograms), local and loco-regional anaesthesia in dental procedures, adults and adolescents (12 to 18 years): for a routine procedure the normal dose for adult patients is 1 cartridge, but the contents of less of a cartridge may be sufficient for effective anaesthesia; for more extensive procedures more cartridges may be required, at the discretion of the dentist, without exceeding the maximum recommended dose
Route: Infiltration and perineural injection in the oral cavity (dental local and loco-regional anaesthesia)
Frequency: Single injection for the procedure (dose determined on an individual basis; lowest dose leading to effective anaesthesia); inject very slowly (1 ml/min) with prior aspiration
Max: 7 mg/kg articaine with an absolute maximum articaine dose of 500 mg (adults and adolescents 12 to 18 years)
STRENGTH SCOPE: only the 1:200,000 adrenaline strength is covered. The page names adrenaline 1:100,000 or 1:200,000, but the pinned SPC dosing is for the 1:200,000 product only; the SPC states that 'Septanest/Artikent/Bartinest/Isonest 1:100,000 is also available and is preferable for use in more complex procedures, such as requiring pronounced hemostasis', and the 1:100,000 product's own SPC is NOT covered here. §4.1 (verbatim): 'Local and loco-regional anaesthesia in dental procedures. Septanest/Artikent/Bartinest/Isonest 1:200,000 is indicated in adults, adolescents and children above 4 years of age (or from 20 kg (44 lbs) of body weight).' §2 (verbatim): 'Per 1.7 ml cartridge Per 2.2 ml cartridge Articaine hydrochloride (INN) 68.000 mg 88.000 mg ... Adrenaline tartrate (expressed in base) 8.50 micrograms (1:200 000) 11.00 micrograms (1:200 000)'. VERBATIM §4.2: 'For professional use by physicians or dentists only.' 'For all populations, the lowest dose leading to effective anaesthesia should be used. The necessary dosage must be determined on an individual basis. For a routine procedure, the normal dose for adult patients is of 1 cartridge, but the contents of less of a cartridge may be sufficient for effective anaesthesia. At the discretion of the dentist, more cartridges may be required for more extensive procedures without exceeding the maximum recommended dose.' 'Septanest/Artikent/Bartinest/Isonest 1:200,000 is indicated for use in most routine dental procedures.' 'In adults and adolescents, the maximum articaine dose is 7 mg/kg with an absolute maximum articaine dose of 500 mg. The maximum articaine dose of 500 mg corresponds to a healthy adult of more than 70 kg body weight.' Printed maximum-dose table (adults and adolescents; body weight, maximum articaine hydrochloride, adrenaline dose, total volume): 40 kg, 280 mg, 0.035 mg, 7.0 ml (4.1 cartridges of 1.7 ml; 3.1 cartridges of 2.2 ml); 50 kg, 350 mg, 0.044 mg, 8.8 ml (5.2; 4); 60 kg, 420 mg, 0.053 mg, 10.5 ml (6.2; 4.7); 70 kg or more, 490 mg, 0.061 mg, 12.3 ml (7.0; 5.5). The table lists 490 mg for 70 kg or more while the text prints an absolute maximum of 500 mg; both are as printed. CONCOMITANT SEDATIVES (§4.2): 'The maximum safe dose of local anaesthetics may be reduced in sedated patients due to an additive effect on central nervous system depression (see section 4.5).' METHOD (§4.2): 'Infiltration and perineural use in oral cavity. Local anaesthetics should be injected with caution when there is inflammation and/or infection at the site of the injection. The rate of injection should be very slow (1 ml/min).' 'When using Septanest/Artikent/Bartinest/Isonest 1:200,000 for infiltration or regional block anaesthesia, injection should always be made slowly and with prior aspiration.' 'This medicinal product should only be used by or under the supervision of physicians or dentists sufficiently trained and familiar with diagnosis and treatment of systemic toxicity. The availability of appropriate resuscitation equipment and medication should be ensured before induction of regional anaesthesia with local anaesthetics to enable prompt treatment of any respiratory and cardiovascular emergencies.' 'The patient's state of consciousness should be monitored after each local anaesthetic injection.' TRUNCATION: §4.2, §4.3, §4.6 and §2 were retrieved in full; the retrieved §4.4 ends part-way through the intravascular-injection precaution, §4.5 ends at the ergot-type oxytocic entry and §4.8 ends part-way through the musculoskeletal entries at the source-fetch limit, so the safety lists below are partial. Paediatric and special-population information is in the paediatric block and the renal / hepatic fields.

Paediatric dose

Dose: Children 4 to 11 years of age (or from 20 kg body weight), dental anaesthesia with the 1:200,000 product: the quantity to be injected is determined by the age and weight of the child and the magnitude of the operation; the SPC prints an average effective dose of articaine of 2 mg/kg for simple procedures and 4 mg/kg for complex procedures; use the lowest dose providing effective dental anaesthesia
Route: Infiltration and perineural injection in the oral cavity
Frequency: Single injection for the procedure; inject very slowly (1 ml/min)
Max: 7 mg/kg articaine only, with an absolute maximum of 385 mg articaine for a healthy child of 55 kg body weight
As printed in SPC §4.2 (Children 4 to 11 years of age), not scaled from the adult dose. Verbatim: 'The safety of Septanest/Artikent/Bartinest/Isonest 1:200,000 in children aged 4 years and below has not been established. No data are available. The quantity to be injected should be determined by the age and weight of the child and the magnitude of the operation. The average effective dose of articaine is 2 mg/kg and 4 mg/kg for simple and complex procedures, respectively. The lowest dose providing effective dental anaesthesia should be used. In children aged 4 years (or from 20 kg (44 lbs) of body weight) and above, the maximum dose of articaine is 7 mg/kg only with an absolute maximum dose of 385 mg articaine for a healthy child of 55 kg body weight.' Printed maximum-dose table for children (body weight, maximum articaine hydrochloride, adrenaline dose, total volume): 20 kg, 140 mg, 0.018 mg, 3.5 ml (2.1 cartridges of 1.7 ml; 1.5 cartridges of 2.2 ml); 30 kg, 210 mg, 0.026 mg, 5.3 ml (3.1; 2.4); 40 kg, 280 mg, 0.035 mg, 7.0 ml (4.1; 3.1); 55 kg or more, 385 mg, 0.048 mg, 9.6 ml (5.6; 4.3). No dose is given for children aged 4 years and below, or below 20 kg. Risk of biting trauma (lips, cheeks, mucosa and tongue) exists, especially in children (§4.4).

Dose adjustments

Renal

No numerical renal dose adjustment is printed. §4.2: 'Due to the lack of clinical data, particular precaution should be used in order to administer the lowest dose leading to effective anaesthesia in elderly patients and in patients with renal disorders (section 4.4 and 5.2). Elevated product plasma levels may occur in these patients in particular after repeated use. In case of required reinjection, patient should be strictly monitored, to identity any sign of relative overdose (see section 4.9).' §4.4: patients with renal disease, the lowest dose leading to effective anaesthesia should be used.

Hepatic

No numerical hepatic dose adjustment is printed. §4.2: 'Particular precaution should be used in order to administer the lowest dose leading to efficient anaesthesia in patients with hepatic impairment, in particular after repeated use, although 90% of articaine is first inactivated by unspecific plasma esterases in the tissue and blood.' §4.4: in severe hepatic disease the product should be used cautiously.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to articaine (or any local anaesthetic agent of the amide type), to adrenaline or to any of the excipients listed in section 6.1 (§4.3)
  • Patients with epilepsy not controlled by treatment (§4.3)

Side effects

  • Adverse reactions are similar to those observed with other local amide anaesthetics / vasoconstrictors and are, in general, dose-related; they may also result from hypersensitivity, idiosyncrasy or diminished tolerance. Nervous system disorders, local injection site reaction, hypersensitivity, cardiac disorders and vascular disorders are the most frequently occurring; serious adverse reactions are generally systemic (§4.8)
  • Common (as read in the extracted table): gingivitis; neuropathy including neuralgia (neuropathic pain), hypoesthesia / numbness (oral and perioral), hyperesthesia, dysesthesia (oral and perioral) including dysgeusia (e.g. taste metallic, taste disturbance), ageusia, allodynia, thermohyperesthesia; headache; bradycardia; tachycardia; hypotension (with possible circulatory collapse); swelling of tongue, lip, gums (§4.8)
  • Uncommon (as read): burning sensation; hypertension; stomatitis, glossitis; nausea, vomiting, diarrhoea; rash (eruption), pruritus; neck pain (§4.8)
  • Rare (as read): allergic, anaphylactic / anaphylactoid reactions; nervousness / anxiety; facial nerve disorder (palsy, paralysis and paresis); Horner's syndrome (eyelid ptosis, enophthalmos, miosis); somnolence (drowsiness); nystagmus; diplopia (paralysis of oculomotor muscles); visual impairment (temporary blindness); ptosis; miosis; enophthalmos; hyperacusis; tinnitus; palpitations; hot flush; bronchospasm / asthma; dyspnoea; gingival / oral mucosal exfoliation (sloughing) / ulceration; angioedema (face / tongue / lip / throat / larynx / periorbital oedema); urticaria; muscle twitching (§4.8)
  • Very rare (as read): paresthesia (persistent hypoesthesia and gustatory loss) after mandibular or inferior alveolar nerve blocks (§4.8)
  • Not known (as read): euphoric mood; conduction disorders (atrioventricular block); local / regional hyperaemia; vasodilatation; vasoconstriction; dysphonia (hoarseness); dysphagia; swelling of cheeks; glossodynia; erythema; hyperhidrosis; aggravation of the neuromuscular manifestations (text cut off) (§4.8)
  • The extracted §4.8 table lost its column layout and footnote markers, and the section is cut at the source-fetch limit, so the frequency-to-term pairing above should be checked against the SPC and the list is partial
  • Adrenaline impairs the flow of blood in the gums, potentially causing local tissue necrosis; very rare cases of prolonged or irreversible nerve injury and gustatory loss have been reported after mandibular block analgesia (§4.4)
  • Sodium metabisulfite (excipient) may rarely cause hypersensitivity reactions and bronchospasm (§4.4)
  • Risk of biting trauma (lips, cheeks, mucosa and tongue), especially in children; the patient should avoid chewing gum or eating until normal sensation is restored (§4.4)

Interactions

  • Other local anaesthetics: toxicity is additive; the total dose of all local anaesthetics administered should not exceed the maximum recommended dose of the drugs used (§4.5)
  • Sedatives (CNS depressants, e.g. benzodiazepines, opioids): additive CNS depression; use reduced doses of anaesthetic (§4.5, §4.2)
  • Halogenated volatile anaesthetics (e.g. halothane): use reduced doses because of sensitisation of the heart to the arrhythmogenic effects of catecholamines (risk of severe ventricular arrhythmia); discuss with the anaesthetist before local anaesthetic administration during general anaesthesia (§4.5)
  • Postganglionic adrenergic blocking agents (e.g. guanadrel, guanethidine, rauwolfia alkaloids): use reduced doses under strict medical supervision with careful aspiration; risk of hypertension and other cardiovascular effects (§4.5)
  • Non-selective beta-adrenergic blockers (e.g. propranolol, nadolol): use reduced doses; possible increase in blood pressure and increased risk of bradycardia (§4.5)
  • Tricyclic antidepressants (e.g. amitriptyline, desipramine, imipramine, nortriptyline, maprotiline, protriptyline): reduce dose and rate of administration because of increased risk of severe hypertension (§4.5)
  • COMT inhibitors (e.g. entacapone, tolcapone): arrhythmias, increased heart rate and blood pressure variations may occur; give a reduced amount of adrenaline (§4.5)
  • MAO inhibitors (A-selective, e.g. moclobemide, and non-selective, e.g. phenelzine, tranylcypromine, linezolid): if concurrent use cannot be avoided, reduce dose and rate of administration and use under strict medical supervision because of the risk of hypertensive crisis (§4.5)
  • Drugs causing arrhythmias (e.g. antiarrhythmics such as digitalis, quinidine): reduce the dose because of the increased risk of arrhythmia with adrenaline; careful aspiration prior to administration is recommended (§4.5)
  • Ergot-type oxytocic drugs (e.g. methysergide, ergotamine, ergonovine): the retrieved §4.5 text is cut off at this entry and the advice was not retrieved

Monitoring

  • Make inquiries into the patient's current therapies and history, maintain verbal contact with the patient and have resuscitative equipment at hand (§4.4)
  • Monitor the patient's state of consciousness after each local anaesthetic injection (§4.2)
  • Lowest effective dose in patients with cardiac impulse formation and conduction disturbances, acute decompensated heart failure, hypotension, paroxysmal tachycardia or absolute arrhythmias with rapid heart rate, unstable angina or myocardial infarction within 6 months, coronary artery bypass surgery within 3 months, non-cardioselective beta-blockers, uncontrolled hypertension, or concomitant tricyclic antidepressants; consider postponing dental surgery if the condition is severe and/or unstable (§4.4)
  • Strictly monitor any patient who needs reinjection (elderly, renal disorder, cholinesterase deficiency) for signs of relative overdose (§4.2, §4.4)
  • Plasma cholinesterase deficiency can be suspected when clinical signs of overdose occur with the usual dose and a vascular injection has been excluded; use a reduced dose for the next injection (§4.4)
  • Consider the 1:200,000 product over 1:100,000 (adrenaline 5 micrograms/ml) in patients with cardiovascular disease, cerebral circulation disturbances or history of stroke; defer dental treatment with articaine/adrenaline for six months following a stroke; use cautiously in uncontrolled diabetes, thyreotoxicosis, phaeochromocytoma and susceptibility to acute angle-closure glaucoma (§4.4)
  • Use with caution in patients taking antiplatelet / anticoagulant medicines or with coagulation disorders (higher risk of bleeding, more associated with the procedure than the medicine); use only in acute porphyria when no safer alternative is available (§4.4)
  • Reduce the dose in hypoxia, hyperkalaemia and metabolic acidosis; the local anaesthetic effect may be reduced in inflamed or infected tissue (§4.4)

Clinical monograph

How it works

Articaine reversibly blocks voltage-gated sodium channels in nerve fibres to prevent impulse conduction, while the added adrenaline causes local vasoconstriction that prolongs anaesthesia and reduces systemic absorption of the local anaesthetic.

Prescribing in practice

  • Avoid inadvertent intravascular injection, which can cause systemic local-anaesthetic and adrenaline toxicity; aspirate before injecting and use the lowest effective volume.
  • The adrenaline component warrants caution in cardiovascular disease, hyperthyroidism and in patients taking tricyclic antidepressants or non-selective beta-blockers, where pressor effects may be exaggerated.
  • Articaine is metabolised largely by plasma esterases; use cautiously where there is methaemoglobinaemia risk and follow the SPC for population-specific limits.

Monitoring

Observe the patient during and after injection for signs of systemic toxicity, vasovagal reactions or excessive cardiovascular stimulation.

Counselling the patient

  • Numbness of the lips, tongue and cheek will persist for some time after the procedure, so avoid biting the area or taking hot drinks until sensation returns.
  • Report palpitations, dizziness or feeling faint promptly.

Evidence & guidelines

Use is supported by established dental anaesthesia practice and the product SPC; articaine with adrenaline is a widely used dental local anaesthetic.

Reference: AAGBI Safety Guideline – Local Anaesthetic Toxicity 2010; SmPC Septanest; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.